SCHEMBL30714710

SCHEMBL30714710

Cn1nc2ccc(OCc3ccccc3)cc2c1C(=O)NCCN1CCOC1=O

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 3/20 0.44
FAAH O00519 1/20 0.43
SCN9A Q15858 1/20 0.43
ALDH1A1 P00352 2/20 0.43
POLB P06746 2/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
KMT2A Q03164 1/20 0.43
NMT1 P30419 3/20 0.42
NMT2 O60551 1/20 0.42
HTR3A P46098 2/20 0.41
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
MMP13 P45452 1/20 0.40
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714743 0.87 SCN9A (0.42) SCN9AALDH1A1POLBMAPTLMNA
SCHEMBL30714645 0.85 SCN9A (0.41) SCN9AALDH1A1POLBMAPTLMNA
SCHEMBL30714746 0.84 SCN9A (0.45) SCN9AALDH1A1POLBMAPTLMNA
SCHEMBL30656256 0.80 NAAA (0.44) NAAAFAAHSCN9AALDH1A1POLB
SCHEMBL30714584 0.78 KDM5B (0.49) ALDH1A1POLBMAPTLMNANMT1
SCHEMBL26696088 0.76 SRD5A2 (0.50) KMT2ANMT1NMT2MAOB
SCHEMBL30714592 0.76 EGLN2 (0.45) ALDH1A1KMT2ANMT1HTR3AMMP13
SCHEMBL30714713 0.76 HTR3A (0.51) HTR3AMAOAMAOB
SCHEMBL30714647 0.75 SLC6A5 (0.51) LMNAKMT2ANMT1HTR3AMMP13
SCHEMBL31539883 0.75 HTR3A (0.41) MAPTLMNAKMT2ANMT1NMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 NAAA 1293/4885FAAH 581/4885SCN9A 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.